We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
Cap. Flow
+$193M
Cap. Flow %
40.57%
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$7.96M
2
AMGN icon
Amgen
AMGN
+$5.99M
3
AZTA icon
Azenta
AZTA
+$5.35M
4
ESTA icon
Establishment Labs
ESTA
+$5.33M
5
CNC icon
Centene
CNC
+$5.26M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$3.59M
2
HOLX
Hologic
HOLX
+$3.48M
3
ATHN
Athenahealth, Inc.
ATHN
+$3.34M
4
AGN
Allergan plc
AGN
+$3.33M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Industrials 0.59%
3 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
101
DELISTED
Molecular Templates, Inc.
MTEM
$522K 0.11%
+6,461
New +$495K
EIGR
102
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$486K 0.1%
1,350
+17
+1% +$5.82K
ACET
103
DELISTED
Aceto Corp
ACET
$478K 0.1%
+211,624
New +$676K
VRCA icon
104
Verrica Pharmaceuticals
VRCA
$89.7M
$325K 0.07%
+2,000
New +$342K
CLSD
105
DELISTED
Clearside Biomedical
CLSD
$311K 0.07%
+3,375
New +$401K
UROV
106
DELISTED
Urovant Sciences Ltd.
UROV
$120K 0.03%
+10,000
New +$118K
ANGO icon
107
AngioDynamics
ANGO
$651M
– –
-50,842
Closed -$1.13M
ARDX icon
108
Ardelyx
ARDX
$1.02B
– –
-100,000
Closed -$370K
BLUE
109
DELISTED
bluebird bio
BLUE
– –
-386
Closed -$785K
BSX icon
110
CALL
Boston Scientific
BSX
$74.2B
– –
-200,000
Closed -$6.54M
CHRS icon
111
PUT
Coherus Oncology
CHRS
$187M
– –
-97,500
Closed -$1.36M
CNC icon
112
CALL
Centene
CNC
$32.1B
– –
-100,000
Closed -$6.16M
COLL icon
113
Collegium Pharmaceutical
COLL
$843M
– –
-52,219
Closed -$1.25M
CORT icon
114
PUT
Corcept Therapeutics
CORT
$12.1B
– –
-100,200
Closed -$1.57M
CYTK icon
115
CALL
Cytokinetics
CYTK
$10.6B
– –
-24,600
Closed -$204K
FOLD
116
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-50,000
Closed -$781K
GERN icon
117
PUT
Geron
GERN
$1.05B
– –
-200,000
Closed -$686K
GKOS icon
118
CALL
Glaukos
GKOS
$10.7B
– –
-76,200
Closed -$3.1M
GKOS icon
119
Glaukos
GKOS
$10.7B
– –
-50,000
Closed -$2.03M
HOLX
120
CALL
DELISTED
Hologic
HOLX
– –
-50,000
Closed -$1.99M
HOLX
121
DELISTED
Hologic
HOLX
– –
-87,500
Closed -$3.48M
MRK icon
122
Merck
MRK
$322B
– –
-31,440
Closed -$1.82M
MTD icon
123
PUT
Mettler-Toledo International
MTD
$28.8B
– –
-10,000
Closed -$5.79M
RCKT icon
124
Rocket Pharmaceuticals
RCKT
$384M
– –
-51,459
Closed -$1.01M
SRPT icon
125
Sarepta Therapeutics
SRPT
$1.92B
– –
-16,000
Closed -$2.12M
3 4
5
6 7

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.

  • Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
  • Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
  • Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
  • Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.

Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.